JP2009504748A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504748A5
JP2009504748A5 JP2008527061A JP2008527061A JP2009504748A5 JP 2009504748 A5 JP2009504748 A5 JP 2009504748A5 JP 2008527061 A JP2008527061 A JP 2008527061A JP 2008527061 A JP2008527061 A JP 2008527061A JP 2009504748 A5 JP2009504748 A5 JP 2009504748A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
tetrahydrobenzathiazole
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008527061A
Other languages
English (en)
Other versions
JP2009504748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/031831 external-priority patent/WO2007022182A1/en
Publication of JP2009504748A publication Critical patent/JP2009504748A/ja
Publication of JP2009504748A5 publication Critical patent/JP2009504748A5/ja
Withdrawn legal-status Critical Current

Links

Claims (8)

  1. 神経変性疾患を有する子供および成人における神経、筋肉（心臓および横紋筋）および／または網膜組織機能を回復する方法において使用するための、以下：
    Figure 2009504748
     で示される化学式を有するテトラヒドロベンザチアゾールまたはその薬学的に受容可能な塩を含む、薬学的組成物であって、式中、
    Ｒ１、Ｒ２、Ｒ３、およびＲ４が、Ｈ、Ｃ１−Ｃ３アルキル、およびＣ１−Ｃ３アルケニルからなる群から独立に選択され、
    −Ｎ（Ｒ ３ ）（Ｒ ４ ）基が６位にある、
    薬学的組成物。
  2. Ｒ（＋）エナンチオマーのエナンチオマー過剰が９９％より大きい、請求項１に記載の薬学的組成物。
  3. 前記テトラヒドロベンザチアゾールが、プラミペキソールのＲ（＋）エナンチオマーである、請求項１または２に記載の薬学的組成物。
  4. 局所投与、経皮投与、経腸投与、または非経口投与に適する、請求項１〜３のいずれか一項に記載の薬学的組成物。
  5. 前記テトラヒドロベンザチアゾールまたはその薬学的に受容可能な塩が、１０ｍｇと１００ｍｇとの間の単回投薬量の経腸投与のための投薬処方物で提供される、請求項４に記載の薬学的組成物。
  6. 前記テトラヒドロベンザチアゾールまたはその薬学的に受容可能な塩が、１０ｍｇ／日と５００ｍｇ／日との間の連続静脈内注入による単回投薬量の非経口投与のための投薬処方物で提供される、請求項４に記載の薬学的組成物。
  7. 前記投薬処方物が３０ｍｇのプラミペキソールを含む、請求項５に記載の薬学的組成物。
  8. 前記神経変性疾患が、アルツハイマー病、パーキンソン病または筋萎縮性側索硬化症である、請求項１〜７のいずれか一項に記載の薬学的組成物。
JP2008527061A 2005-08-15 2006-08-15 Ｒ（＋）プラミペキソールを用いた神経回復 Withdrawn JP2009504748A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70821305P 2005-08-15 2005-08-15
PCT/US2006/031831 WO2007022182A1 (en) 2005-08-15 2006-08-15 Neurorestoration with r(+) pramipexole

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012233610A Division JP2013014629A (ja) 2005-08-15 2012-10-23 Ｒ（＋）プラミペキソールを用いた神経回復

Publications (2)

Publication Number Publication Date
JP2009504748A JP2009504748A (ja) 2009-02-05
JP2009504748A5 true JP2009504748A5 (ja) 2009-10-01

Family

ID=37428609

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008527061A Withdrawn JP2009504748A (ja) 2005-08-15 2006-08-15 Ｒ（＋）プラミペキソールを用いた神経回復
JP2012233610A Pending JP2013014629A (ja) 2005-08-15 2012-10-23 Ｒ（＋）プラミペキソールを用いた神経回復

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012233610A Pending JP2013014629A (ja) 2005-08-15 2012-10-23 Ｒ（＋）プラミペキソールを用いた神経回復

Country Status (10)

Country Link
US (3) US20080234338A1 (ja)
EP (1) EP1917014B1 (ja)
JP (2) JP2009504748A (ja)
AT (1) ATE444750T1 (ja)
AU (1) AU2006279643B2 (ja)
CA (1) CA2619217A1 (ja)
DE (1) DE602006009670D1 (ja)
ES (1) ES2334061T3 (ja)
IL (1) IL189512A (ja)
WO (1) WO2007022182A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004121177A (ru) * 2001-12-11 2005-03-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн (Us) Применение прамипексола для лечения бокового амитрофического склероза
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EA201001083A1 (ru) 2004-08-13 2011-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
SG164375A1 (en) 2004-08-13 2010-09-29 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
DE602006009670D1 (de) * 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
EP2497473A1 (en) * 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and pharmaceutical compositions thereof
CN101448498B (zh) 2006-05-16 2011-04-27 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
CN102772404A (zh) * 2006-12-14 2012-11-14 诺普神经科学股份有限公司 (r)-普拉克索的组合物以及使用该组合物的方法
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113003A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20100130569A1 (en) * 2007-05-11 2010-05-27 Saten Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
CN102186350A (zh) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
AU2010234244A1 (en) * 2009-04-09 2011-10-13 Purdue Pharma Once-daily oral IR/CR pramipexole formulation
CA2765876A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3838271A1 (en) 2013-07-12 2021-06-23 Knopp Biosciences LLC Treating elevated levels of eosinophils and/or basophils
CA2921378A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
WO2016194015A2 (en) * 2015-06-04 2016-12-08 Chiarugi Alberto Use of r(+)-pramipexole (dexpramipexole) for the treatment of cerebral ischemia of the focal type
JP2020512390A (ja) * 2017-03-27 2020-04-23 チェイス セラピューティクス コーポレイション シヌクレイノパチーを処置するための組成物および方法
IL312486A (en) 2017-04-10 2024-07-01 Chase Therapeutics Corp NK1 antagonist combination and a method for the treatment of synucleinopathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
CZ293360B6 (cs) * 1995-10-26 2004-04-14 Sanofi-Synthelabo Léčivo pro léčení amyotrofické laterální sklerózy
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
CA2415815A1 (en) * 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
US20020151526A1 (en) * 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
RU2004121177A (ru) * 2001-12-11 2005-03-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн (Us) Применение прамипексола для лечения бокового амитрофического склероза
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
KR101152183B1 (ko) * 2003-03-31 2012-06-15 타이탄 파머슈티컬즈 인코퍼레이티드 도파민 아고니스트의 지속 방출을 위한 이식가능한 폴리머디바이스
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
SG164375A1 (en) * 2004-08-13 2010-09-29 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE602006009670D1 (de) * 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol

Similar Documents

Publication Publication Date Title
JP2009504748A5 (ja)
JP2008545793A5 (ja)
JP2003509349A5 (ja)
JP2020512337A5 (ja)
JP2008536844A5 (ja)
JP2015505296A5 (ja)
JP2013542247A5 (ja)
JP2013508279A5 (ja)
JP2016534063A5 (ja)
JP2013510885A5 (ja)
JP2009535352A5 (ja)
JP2012530779A5 (ja)
JP2014517050A5 (ja)
JP2020505423A5 (ja)
JP2007519649A5 (ja)
JP2019515908A5 (ja)
JP2011051993A5 (ja)
JP2017511339A5 (ja)
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
JP2010521417A5 (ja)
JP2019516739A5 (ja)
JP2007530703A5 (ja)
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
JP2013514980A5 (ja)
JP2013536833A5 (ja)